证券研究报告 | 2025年12月22日 医药生物周报（25 年第 49 周） 优于大市 政策端支持服务消费力度提升，关注医疗服务相关机会 本周医药板块表现弱于整体市场，化学制药跌幅居前。本周全部 A 股下 跌 0.07%（总市值加权平均），沪深 300 下跌 0.28%，中小板指下跌 0.80%，创业板指下跌 2.26%，生物医药板块整体下跌 0.14%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 1.74%，生物 制品下跌 0.67%，医疗服务上涨 0.55%，医疗器械上涨 1.16%，医药商 业上涨 4.94%，中药上涨 0.17%。医药生物市盈率（TTM）37.07x，处 于近 5 年历史估值的 79.04%分位数。 近两年我国密集出台支持服务消费的政策，围绕"稳增长、扩内需、提 质量"，持续释放服务消费潜力。政策一方面从供给侧入手，通过扩大 和优化服务供给、放宽准入、提升服务质量与效率，推动医疗、养老、 文旅等重点领域升级；另一方面通过财政、金融和价格等工具，加大对 居民消费和服务业主体的支持，降低成本、激发需求。在此背景下，"犒 赏经济"成为新亮点，居民在满足基本需求后，更愿为健康 ...

"年度创新力奖"旨在表彰资本市场最具有突破性、创新性的企业。创新是企业的核心竞争力，想要不 凡，就必须在技术研发、产品、商业模式等方面做出创新。本奖项从创新的广度、深度等多维度出发， 甄选出的企业都致力于探索前沿科技，开辟发展新路径，引领行业前行，推动社会进步。本次评选通过 定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角 兽公司排行榜。此次"金格奖"上市公司评选覆盖港交所、上交所、深交所、纽交所、美国证券交易所、 纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜 单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选中，光峰科技(688007.SH)、康宁杰瑞制药- B(09966.HK)、KEEP(03650.HK)、迈瑞医疗(300760.SZ)、瑞和数智(03680.HK)、瑞声科技 (02018.HK)、三七互娱(002555.SZ)、通威股份(600438.SH)、星环科技-U(688031.SH)、云顶新耀 ...

中信建投证券研报指出，迈瑞医疗是国内医疗器械领域龙头公司，多个产品领域市占率国内领先。短期 来看，公司迎来长周期拐点，25Q3收入同比增速转正，25Q4增速有望进一步提升，2026年有望回归稳 健增长，在业绩修复、港股上市、战略转型背景下实现估值重塑。中长期来看，数智化、流水化、国际 化三大战略布局清晰，业务结构由设备销售为主向可持续、复购型收入模式升级，将打开更大的成长天 花板；公司研发创新、销售管理、国际化和并购能力已得到充分验证，全球市场份额将持续提升、加速 迈向全球医疗器械Top10，2026年港股上市将进一步提升全球影响力、优化股东结构。维持"买入"评 级。 ...

Core Viewpoint - The article highlights the recent measures taken by various regions to boost consumer spending ahead of the traditional consumption peak season, leading to a rebound in the large consumer sector in the capital market [1] Group 1: Market Performance - The large consumer index rose by 1.33% on December 19, significantly outperforming the Shanghai Composite Index [1] - Sub-sectors such as dairy, retail, and beverage manufacturing saw substantial increases, with Kweichow Moutai, a representative of large consumption, achieving a cumulative increase of 2.36% since December 10 [1] Group 2: Financing and Investment Trends - As of December 18, the total financing balance for the 87 constituent stocks of the large consumer index approached 320 billion yuan, representing an increase of over 45% compared to the end of last year, with over 70% of the financing targets seeing increased investment [1] - Notable stocks such as Rongchang Biologics, Sanhua Intelligent Control, and Sunshine Power experienced financing balance increases exceeding 100% [1] Group 3: Institutional Research and Stock Performance - There are 12 stocks with a financing balance increase of no less than 20%, having received research from 20 or more institutions this year, and with a year-to-date increase of less than 25% [1] - The leading companies in terms of institutional research are Huichuan Technology, Mindray Medical, and Hikvision, with the number of institutional research counts being 1654, 989, and 519 respectively [2]

Group 1 - The core viewpoint of the articles highlights the recovery and growth potential of the consumer sector, driven by policy support and increasing consumer demand during the traditional consumption peak season [1][5][6] - The consumer sector index showed signs of stabilization and rebound, with a 1.33% increase on December 19, outperforming the Shanghai Composite Index [2] - The consumer market is expected to see double-digit growth over the next two years, with retail sales projected to rise from 39.1 trillion yuan in 2020 to 48.3 trillion yuan by 2024, reflecting an average annual growth rate of 5.5% [5][6] Group 2 - The consumer sector is currently experiencing a valuation adjustment, with the consumer index's latest price-to-earnings ratio at 23.29, significantly below the 10-year average of 28.56 [6] - Institutional predictions indicate that the net profit growth for the consumer sector index constituents is expected to exceed 14% in 2026 and 2027, with a projected total net profit of nearly 460 billion yuan for 2025 [6] - A total of 87 stocks in the consumer sector have seen an average increase of over 28% this year, with significant contributions from the electronics and biopharmaceutical sectors [8] Group 3 - Notable stocks such as 汇川技术 (Inovance Technology) and 迈瑞医疗 (Mindray) have received substantial institutional attention, with the former seeing a 22.91% increase in stock price and over 1,600 institutional surveys this year [9][11] - The financing balance for the consumer sector stocks has increased by over 45% compared to the end of last year, with more than 70% of the stocks receiving additional financing [8][11] - Companies like 东鹏饮料 (Eastroc Beverage) are expanding their product lines and exploring overseas markets, indicating a strategic focus on growth and market penetration [10]

数据统计，从2011年上市至今，三七互娱累计分红27次，累计现金分红总额超过115亿元。三七互娱12 月11日公告称，公司全资子公司安徽泰运拟向帝奥微湖杉（嘉兴）股权投资合伙企业（有限合伙）进行 投资，出资额不超过5000万元。帝奥微湖杉基金目标认缴总规模为3亿元，但不超过4亿元，最终以实际 募集情况为准。本次投资帝奥微湖杉基金后，帝奥微湖杉基金将投资于AI产业链相关企业。 数据统计，从2016年上市至今，玲珑轮胎累计分红15次，累计现金分红总额超过36.91亿元。玲珑轮胎 12月11日发布2025年第三季度权益分派实施公告，本次利润分配以方案实施前的公司总股本14.64亿股 为基数，每股派发现金红利0.065元（含税），共计派发现金红利9512.77万元。 | 证券简称 | 分红总额 | 分红次数 | Wind行业 | | --- | --- | --- | --- | | | (亿元) | | | | 三七互娱 | 13. 86 | 3 | 传媒 | | 玲珑轮胎 | 3.59 | 3 | 汽车与零配件 | | 迈瑞医疗 | 49. 35 | 3 | 医疗设备与服务 | | 御银股份 | 0. 05 | ...

智通财经12月21日讯（编辑 笠晨）近年来A股上市公司分红意愿显著提升，市场分红生态持续优化，呈 现出分红总额、参与分红公司数量占比以及年内多次分红公司数量逐年递增的趋势。choice数据统计， 截至发稿，以股权登记日计算，今年以来A股上市公司现金分红总额达到2.61万亿元，已超过2024年全 年，创出历史新高。 Wind数据显示，今年以来，A股上市公司迈瑞医疗、三七互娱、御银股份和玲珑轮胎分红次数均为三 次。山东路桥、雅戈尔、深圳华强、奕帆传动、陕国投A、鱼跃医疗、行动教育、南山铝业、隆扬电 子、艾融软件、分众传媒、药明康德、百龙创园、吉比特、华宝股份、新坐标、龙佰集团、远翔新材、 华明装备、卓创资讯、九强生物、金帝股份、开普检测、西部证券、海希通讯、开能健康、金能科技、 金岭矿业、国光股份和吉电股份分红次数均为两次。具体情况如下图： | 证券简称 | 分红总额 | 分红次数 | Wind行业 | | --- | --- | --- | --- | | | (亿元) | | | | 三七互娱 | 13. 86 | 3 | 传媒 | | 玲珑轮胎 | 3.59 | 3 | 汽车与零配件 | | 迈瑞医疗 | ...

Investment Rating - The report maintains a positive outlook on the insomnia treatment market, highlighting the potential for new drug sales performance in this sector [20][32]. Core Insights - The insomnia treatment market in China is characterized by a significant unmet need, with over 200 million individuals estimated to suffer from insomnia symptoms, representing a large consumer market potential [16][24]. - The report emphasizes the shift towards innovative insomnia medications, particularly focusing on new types of benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs) as key areas for development [25][38]. - The introduction of new drugs like JY-202 (地达西尼) and DORA medications is expected to reshape the market dynamics, with a forecasted rapid increase in market share and sales [34][39]. Market Overview - The insomnia drug market in China has seen stagnant growth due to a lack of new effective treatments, with the market size in 2023 estimated at 31.62 billion yuan [24]. - The report outlines the historical sales performance of major insomnia medications, indicating a long gap since the last new product launch in 2007, which has contributed to the current market stagnation [24][25]. - The report projects a significant increase in the market size and sales for innovative insomnia drugs, particularly with the anticipated approval and market entry of new products [34][39]. Drug Development Trends - The report identifies two main directions for insomnia drug innovation: improvements on existing BZRAs and the development of DORAs, which are expected to have lower addiction risks and better patient compliance [25][38]. - The new drug JY-202 is highlighted for its selective action on the GABAA receptor, which may reduce side effects associated with traditional insomnia medications [34]. - The report also notes the successful clinical trial results for DORAs, which have shown significant improvements in sleep quality without the risk of addiction, making them suitable for broader consumer use [38][39]. Key Players and Recommendations - The report suggests focusing on companies like 京新药业 (JY-202) and 先声药业 (DORA medications) as they are positioned to capitalize on the emerging market opportunities in insomnia treatment [34][39]. - It recommends monitoring the sales performance of these new drugs as they enter the market, particularly in the context of changing consumer behavior and increasing awareness of sleep health [20][32].

China healthcare Global Markets Research EQUITY: HEALTH CARE & PHARMACEUTICALS Our thoughts on year ahead 2026 Innovation, that helps Chinese firms go overseas, remains the key theme What is our take on recent sector softness? It is more sentimental than fundamental Over the past three months (early Sept to early Dec), the healthcare sector has lagged the broader market in terms of share price performance. We note that the CSI 300 Health Care index has declined 12% vs CSI 300 up 3%, while the MSCI China Hea ...

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...